Details of the Drug
General Information of Drug (ID: DMQCW7V)
Drug Name |
Tanaproget
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Tanaproget; 304853-42-7; NSP-989; UNII-W9F9H8GXWR; W9F9H8GXWR; 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile; T98; Tanaproget [USAN:INN]; 1zuc; NSP 989; Tanaproget (USAN/INN); AC1NA08O; SCHEMBL62188; CHEMBL539163; GTPL7416; DTXSID00184556; PYVFWTPEBMRKSR-UHFFFAOYSA-N; ZINC6245719; BDBM50375821; AKOS030526776; SB17247; DB04787; CS-1550; NSP-989;NSP 989;NSP989; HY-15606; KB-145966; FT-0735521; W-5758; D06003
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 297.4 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.7 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Estrogen deficiency | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | FB83.0Y | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References